This invention relates in general to medical equipment and procedures. In particular, the invention relates to balloon catheters for use in performing certain endovascular procedures. More particularly, the present invention pertains to balloon catheters with a bypass element.
Temporary balloon occlusion has become a routine and medically accepted technique for the management of patients with aneurysms or intracranial or head/neck tumors. The use of temporary balloon occlusion is particularly useful for the management of patients with aneurysms or intracranial or head/neck tumors who will likely require prolonged intra-operative or permanent occlusion of the internal carotid artery (ICA).
Endovascular procedures are generally less invasive procedure than alternative procedures and are used to treat problems affecting the blood vessels, such as an aneurysm, which is a swelling or “ballooning” of the blood vessel. Typically, the surgery involves making a small incision near each hip to access the blood vessels.
Endovascular procedures replaced clipping surgery for many cerebral aneurysms because it was a less invasive therapeutic procedure. Additionally, it was found that endovascular treatment is often superior because cerebral aneurysms, also called brain aneurysms, are a cerebrovascular issue in which weakness in the walls of a cerebral artery causes localized dilation or ballooning in the blood vessel and can be managed without direct contact with the brain.
Endovascular embolization of intracranial aneurysms initially required the placement of coils via a micro-catheter into the lesion until no additional coils could be placed. Such a procedure resulted in thrombosis and elimination of the aneurysm from the circulation system. This procedure resulted in numerous interstices. Said interstices increase the risk of coil “compaction” and recurrence of aneurysm. In some cases such shortcomings can be surmounted by the use of high-viscosity Onyx liquid embolic material. Onyx is a trade name for a copolymer used for embolisation therapy, which involves the occlusion of blood vessels. It is a liquid embolic agent. Onyx is produced and sold by Medtronic. Onyx consists of Ethylene Vinyl Alcohol Copolymer, soluted in Dimethyl-Sulfoxide (DMSO). Depending on the desired character of the liquid, the concentration can be varied: For example, 6% EVOH (Ethylene Vinyl Alcohol is a copolymer of ethylene and vinyl alcohol that can be used to give additional oxygen and gas barrier properties) and has a trade name of Onyx 18) or 8% EVOH (trade name Onyx 34). In other cases such shortcomings can be surmounted by the use of intrasaccular web devices, hydrogels, or various combinations of these and/or other intrasaccular devices and materials.
More particularly, liquid embolic agent composed of an ethylene vinyl alcohol copolymer dissolved in the organic solvent dimethyl sulfoxide (DMSO) opacified with tantalum powder is used in Onyx. Once coming into contact with an ionic solution the DMSO dissipates and the Onyx solidifies into a spongy, cohesive material. A high viscosity form of Onyx material is now used for the occlusion of some intracranial aneurysms.
After introducing a micro-catheter into the aneurysm, the aneurysm is temporarily occluded by a balloon which reduces the risk of the copolymer exiting the aneurysm and entering the native circulation, and then a viscous forms of Onyx material is delivered to the aneurysm via the micro-catheter.
The prior art contains several catheters with a hole in addition to the end hole. Most of these are taught by twelve patents: U.S. Pat. No. 9,440,043 (Arora et al.); U.S. Pat. Nos. 9,399,112; 9,364,634; 8,496,629; 8,403,911; 6,223,637; 5,954,687; 5,800,407; 5,180,387; 4,970,926; 4,784,638; and 4,755,176.
However, most are designed to drain cerebrospinal fluid from the ventricular through a catheter that enters through a hole in the skull and would not be capable of injecting glue into an artery that enters through the femoral artery and is snaked up through blood vessels in the body. Additionally, the inventions described in said patents could be used to inject something directly into the brain and/or ventricle. However, they could not be used to inject something into an artery within the brain, or to provide a temporary arterial bypass. If it were introduced directly into the artery through the brain it would undoubtedly cause a life threatening bleed in the brain. The medical basis is that a catheter designed to be inserted directly into the brain has no possible role for an intravascular application.
Additionally, the structure of the devices taught by said twelve patent differs from the structure of the present invention. In particular, U.S. Pat. No. 9,440,043 which is a catheter having a tapered structure and balloon formed above a lower drainage hole differ from the present invention because it has a balloon which covers the distal end hole and the present invention does not. U.S. Pat. No. 9,399,112 is a catheter hole having an inclined trailing edge while the present invention does not have an angled side hole. U.S. Pat. No. 9,364,634 teaches an embedded co-extrusion for improving catheter hole array efficiency, whereas the present invention does not use co-extrusions. U.S. Pat. No. 8,496,629 is a catheter which uses staggered diffusion holes a flow breaking feature, the present invention does not require any flow breaking feature. Similarly, U.S. Pat. No. 8,403,911 uses diffusion side holes to improve catheter efficiency, while the present invention does not require any flow breaking feature, including diffusion side holes. U.S. Pat. No. 6,223,637 is a catheter side-wall hole cutting apparatus, whereas the present invention while capable of deploying a device to cut a catheter side-wall has neither a suction element nor a cutting element. U.S. Pat. No. 5,954,687 teach the use of a fluid reservoir, however the present inventions does not. U.S. Pat. No. 5,800,407 is a multiple hole epidural catheter which teaches the use of both permanently opened and permanently closed holes, whereas the present inventions uses holes which can be both opened and closed on a temporary basis in addition to holes which are permanently open. Furthermore, the present invention is designed for intravascular, not epidural use. U.S. Pat. No. 5,180,387 teaches the use of angled holes in a catheter with a non-circular bore, the present invention teaches non-angled holes in a circular bore.
U.S. Pat. No. 4,970,926 teaches an apparatus for making angled hole ventricular catheter which uses a plurality of rods with an end hole in each, where as the present invention teaches the use of side holes. The '638 shows is an angled hole ventricular catheter designed for extended impartment in the brain, whereas the present invention does not use angled holes and is not intended for extended impartment in the brain. U.S. Pat. No. 4,755,176 teaches a catheter with side hole in one of two lumens, whereas the present invention is a single lumen device.
The prior art teaches the use of balloons for flow control in endovascular treatments of target aneurysm. For example, see Moret J, Cognard C, Weill A, Castaings L, Rey A. reported in J Neuroradiol. 1997; 24:30-44 which focused on reconstruction technique in the treatment of wide-neck intracranial aneurysms.
The use of a temporary balloon occlusion is a standard operating procedure when it is desirable to block or closing a blood vessel. It is a medically accepted technique for the management of patients suffering from aneurysms or some intracranial or head/neck tumors. The deployment of a non-detachable silicone balloon catheter is routine to implement temporary a blood vessel closure. Existing, non-detachable silicone balloon catheters are composed of a type of “soft” catheter with an inflatable “balloon” at its tip. The deflated non-detachable silicone balloon catheter is positioned, then inflated to perform the necessary procedure, and deflated again in order to be removed.
The most significant difficulty associated with the use of occlusion balloons for endovascular treatment of aneurysms is the potential for ischemia in the vascular territory when blood flow is occluded by balloon inflations. Thus there is a need to facilitate continued blood flow after placement of a balloon.
This bypass balloon catheter could also allow the tamponading of a bleeding site in a vessel, caused by traumatic injury, iatrogenic injury, spontaneous rupture and/or other disease states, to be tamponaded for prolonged periods while minimizing the risk of ischemic injury to the vascular territory involved. Such temporary tamponade alone can stop the bleeding in some cases. In other cases, such tamponade can temporarily stop the bleeding, allowing additional time for the performance of additional endovascular or open surgical procedures to provide a permanent closure of the bleeding site.
Endovascular treatment of aneurysms with preservation of the parent artery continues to be difficult to implement. The present invention teaches a novel device and simple technique to deploy a balloon delivery catheter across a target aneurysm to facilitate a temporary bypass so as to improve the success rates for endovascular treatments of aneurysms with preservation of the parent artery and while minimizing risks of treatment.
The present invention teaches the use of a bypass element in the catheter to allow continued perfusion of the distal vascular territory while the balloon(s) is(are) inflating. The present invention provides a bypass element to allow continued perfusion of the involved vascular territory while simultaneously completely occluding the neck of an aneurysm with a balloon inflated across its neck, to facilitate treatment of the aneurysm. Furthermore, the device of the current invention has at least one proximal inflow “window” that can also allow delivery of micro-catheters and/or other therapeutic devices to facilitate treatment of such aneurysms.
The present invention also provides a bypass element to allow continued perfusion of the involved vascular territory while simultaneously allowing prolonged balloon inflations that can tamponade an actively bleeding vascular site.
The present invention is composed of a catheter with at least one distal end hole, at least one bypass window proximal to said end hole and a balloon element between said end hole and said bypass window. The present invention is capable of deploying said balloon element, before inflation, across the neck of a target aneurysm while simultaneously positioning said bypass windows proximally of said target aneurysm so as to allow a micro catheter to be pushed from the proximal end of said catheter, through said bypass window, around said balloon and into said target aneurysm. Said micro catheter once deployed is capable of delivering material into said target aneurysm. Once the micro-catheter is in its desired position, the balloon can be inflated to help facilitate the aneurysmal therapy.
Some versions can taper before the bypass windows as well, to allow more flow into the windows, the segment with the balloon can be bigger again or the smaller “tapered down size”, or other variant. Some versions can branch after the proximal bypass “window(s)” to facilitate treatment of lesions at vessel-branching points.
The present invention is composed of a catheter 10 with a distal end hole 50, at least one bypass window 20 proximal to said end hole 50 and a balloon 60 element between said end hole 50 and said bypass window 20. The present invention is capable of deploying said balloon 60 element across the neck of a target aneurysm (shown depending in cutaway profile) while simultaneously positioning said bypass windows 20 proximally of said target aneurysm so as to allow a micro-catheter 30 to be pushed from the proximal end of said catheter 10, through said bypass window 20, around said balloon 60 and into said target aneurysm. Said micro-catheter 30, once deployed, is capable of delivering material into said target aneurysm.
Referring now to
The present invention differs from all prior art due to the incorporation of at least one window element 20 in the catheter just proximal to a deployed balloon 60 element. Said window 20 may be a segment of the present invention's catheter 10 that is composed of two or more struts 22 resulting in one or more window(s) 20.
The present invention adds value to a surgeon because said surgeon can advance the balloon 60 across the neck of an aneurysm or across a bleeding site, then inflate the balloon 60. The balloon 60 tamponades the bleeding and/or allows delivery of coils with balloon 60 remodeling and/or allows “contained” delivery of liquid embolic (Onyx 500) and/or other intrasaccular treatment such as coils, hydrogel, or other intrasaccular therapy, and the balloon 60 does not have to be periodically deflated to allow distal brain perfusion. Instead the “windows” 20 in the catheter 10 proximal to the balloon 60 allow continuous flow of blood during inflation. The blood just flows into the windows 20, through the distal catheter 10 (the segment that has the balloon mounted to it), and out the distal tip 50 of the catheter.
Referring now to
Referring to
In the embodiment of the current invention having a single window 20 bypass, channel 120 or embedded lumen 150 pass directly into balloon 60 element. In an alternate embodiment, additional lumens similar to embedded lumen 150 can be added. The additional lumen can be used for micro-catheters when the joint use of embedded lumen 150 for both balloon 60 inflations and deflations, and passage of a micro-catheter is not desirable.
In the preferred embodiment having a multiple windows 20 are connected by at least one hollow strut 22. In this embodiment, channel 120 or embedded lumen 150 connect through hollow strut 22 to allow flow of inflating material into balloon 60 element. In an alternate embodiment, at least a second window 20 is connected by at least one hollow strut 22. In this embodiment, channel 120 or embedded lumen 150 connect through hollow strut 22 to allow flow of inflating material into balloon 60 element.
Referring to
Referring now to
Referring now to
Additionally, the catheter element of the current invention can even be used simultaneously to access the aneurysm with another micro-catheter 30—with micro-catheter 30 going through the proximal end of catheter 10, then exiting the catheter 10 at a bypass window 20 to access the aneurysm/pathology.
The micro-catheter 30 is advanced over a microwire (not shown), which is soft and steerable. The operator has to steer the microwire in the correct direction. The micro-catheter 30 can be advanced and positioned when the balloon 60 is deflated. Then the microwire can be removed and the balloon 60 can be inflated.
In some non-limiting iterations of the bifurcation/branch point design a treatment micro-catheter with a single or dual lumen can be incorporated into the current device, coming out at the branch point(s). This iteration of the current invention will allow surgeons to ameliorate the adverse affects of targeted aneurysm more quickly, more accurately and at less cost than alternatives taught by prior art.
In some embodiments of the present invention, such as the bifurcated end hole of
In other non-limiting iterations of the present invention, various elements of the present invention can taper before the bypass windows too, to allow more flow into the windows 20. For example the segment with balloon 60 can be bigger again than the smaller “tapered down size”, among other. For added support and stability some embodiments may have additional struts 22 and “windows” 20 distal to the balloon 60 as well to allow the blood flow back into the vessel, with continuing catheter 10 beyond that, that in many embodiments may taper to a smaller catheter size. Thus, the balloon 60 is “stabilized” more and less likely to have its position dislodged by blood flow.
Although the invention has been described in detail in the foregoing embodiments for the purpose of illustration, it is to be understood that such detail is solely for that purpose, and that variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention, except as it may be described by the following claims.
Number | Name | Date | Kind |
---|---|---|---|
4183102 | Guiset | Jan 1980 | A |
4309994 | Grunwald | Jan 1982 | A |
4573966 | Weiki | Mar 1986 | A |
4755176 | Patel | Jul 1988 | A |
4784638 | Ghajar et al. | Nov 1988 | A |
4795427 | Helzel | Jan 1989 | A |
4944745 | Sogard | Jul 1990 | A |
4968306 | Huss | Nov 1990 | A |
4970926 | Ghajar et al. | Nov 1990 | A |
5087247 | Horn | Feb 1992 | A |
5147302 | Euteneuer et al. | Sep 1992 | A |
5163905 | Don Michael | Nov 1992 | A |
5167628 | Boyles | Dec 1992 | A |
5180387 | Ghajar et al. | Jan 1993 | A |
5344402 | Crocker | Sep 1994 | A |
5370617 | Sahota | Dec 1994 | A |
5411479 | Bodden | May 1995 | A |
5460610 | Don Michael | Oct 1995 | A |
5470314 | Walinsky | Nov 1995 | A |
5542925 | Orth | Aug 1996 | A |
5613980 | Chauhan | Mar 1997 | A |
5639274 | Fischell et al. | Jun 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5720735 | Dorros | Feb 1998 | A |
5769828 | Jonkman | Jun 1998 | A |
5800407 | Eldor | Sep 1998 | A |
5830181 | Thornton | Nov 1998 | A |
5840066 | Matsuda | Nov 1998 | A |
5919163 | Glickman | Jul 1999 | A |
5947985 | Imran | Sep 1999 | A |
5951514 | Sahota | Sep 1999 | A |
5954687 | Baudino | Sep 1999 | A |
6013054 | Jiun Yan | Jan 2000 | A |
6017324 | Tu | Jan 2000 | A |
6048333 | Lennox | Apr 2000 | A |
6071285 | Lashinski | Jun 2000 | A |
6086557 | Morejohn | Jul 2000 | A |
6129704 | Forman et al. | Oct 2000 | A |
6146370 | Barbut | Nov 2000 | A |
6193685 | Goodin | Feb 2001 | B1 |
6223637 | Hansen | May 2001 | B1 |
6296655 | Gaudoin et al. | Oct 2001 | B1 |
6364900 | Heuser | Apr 2002 | B1 |
6514281 | Blaeser | Feb 2003 | B1 |
8403911 | Garrison et al. | Mar 2013 | B2 |
8460240 | Towler | Jun 2013 | B2 |
8480619 | Porter | Jul 2013 | B2 |
8496629 | McKinnon et al. | Jul 2013 | B2 |
8747456 | Baim | Jun 2014 | B2 |
8951226 | Hameed | Feb 2015 | B2 |
8956383 | Aklog | Feb 2015 | B2 |
9295818 | Riina | Mar 2016 | B2 |
9364634 | Adams et al. | Jun 2016 | B2 |
9399112 | Shevgoor et al. | Jul 2016 | B2 |
9440043 | Arora et al. | Sep 2016 | B2 |
9579494 | Kersten et al. | Feb 2017 | B2 |
9642673 | Adams et al. | May 2017 | B2 |
9993325 | Ren | Jun 2018 | B2 |
10299824 | Walzman | May 2019 | B2 |
10328246 | Walzman | May 2019 | B1 |
10314684 | Walzman | Jun 2019 | B2 |
10576245 | Walzman | Mar 2020 | B2 |
20020052620 | Barbut | May 2002 | A1 |
20020165572 | Saadat | Nov 2002 | A1 |
20020188276 | Evans | Dec 2002 | A1 |
20030023204 | Vo | Jan 2003 | A1 |
20030097169 | Brucker | May 2003 | A1 |
20030198798 | Hehrlein | Oct 2003 | A1 |
20040006306 | Evans | Jan 2004 | A1 |
20040024347 | Wilson | Feb 2004 | A1 |
20040059278 | McPherson | Mar 2004 | A1 |
20040122465 | McMurtry | Jun 2004 | A1 |
20050038420 | Huybregts | Feb 2005 | A1 |
20050171505 | Bertolero | Aug 2005 | A1 |
20060235459 | Das | Oct 2006 | A1 |
20070038170 | Joseph | Feb 2007 | A1 |
20070185445 | Nahon | Aug 2007 | A1 |
20070197997 | Dua | Aug 2007 | A1 |
20070287967 | Hekmat | Dec 2007 | A1 |
20080039786 | Epstein | Feb 2008 | A1 |
20080125746 | Shapland | May 2008 | A1 |
20080281394 | Jones | Nov 2008 | A1 |
20090209855 | Drilling | Aug 2009 | A1 |
20090209907 | Grata | Aug 2009 | A1 |
20110190727 | Edmunds | Aug 2011 | A1 |
20110245802 | Hayman | Oct 2011 | A1 |
20110276023 | Leeflang | Nov 2011 | A1 |
20120029436 | Yassinzadeh | Feb 2012 | A1 |
20120116352 | Rangi | May 2012 | A1 |
20120136242 | Qi | May 2012 | A1 |
20120302953 | Don Michael | Nov 2012 | A1 |
20120316632 | Gao | Dec 2012 | A1 |
20130158511 | Aggerholm | Jun 2013 | A1 |
20130190796 | Tilson et al. | Jul 2013 | A1 |
20140025151 | Gao | Jan 2014 | A1 |
20140148751 | Kassab et al. | May 2014 | A1 |
20150196303 | Seguin | Jul 2015 | A1 |
20160278783 | Magee | Sep 2016 | A1 |
20160324668 | Wallace et al. | Nov 2016 | A1 |
20170000493 | Boehm | Jan 2017 | A1 |
20170007800 | Chao | Jan 2017 | A1 |
20170086860 | Lee | Mar 2017 | A1 |
20180126130 | Nitzan et al. | May 2018 | A1 |
20180161552 | Larson | Jun 2018 | A1 |
20180229010 | Walzman | Aug 2018 | A1 |
Number | Date | Country |
---|---|---|
WO 2005112823 | Dec 2005 | WO |
Entry |
---|
U.S. Appl. No. 15/258,877, filed Sep. 2016, Walzman. |
Number | Date | Country | |
---|---|---|---|
20180229010 A1 | Aug 2018 | US |
Number | Date | Country | |
---|---|---|---|
62600134 | Feb 2017 | US |